SCHEMBL4254852

SCHEMBL4254852

CC(C)(C)OC(=O)NNc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 10/20 0.60
MEN1 O00255 1/20 0.60
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
KMT2A Q03164 1/20 0.60
ALOX5 P09917 2/20 0.55
CYP3A4 P08684 1/20 0.55
TSHR P16473 1/20 0.55
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
PTGS2 P35354 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
ALOX12 P18054 1/20 0.46
CYP2C19 P33261 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA7 P43166 1/20 0.45
CA14 Q9ULX7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13710304 0.86 GAA (0.51) GAAMEN1NPC1RAB9AKMT2A
SCHEMBL1414807 0.84 MAPT (0.52) GAAMEN1NPC1RAB9AKMT2A
SCHEMBL28578217 0.84 GAA (0.54) GAAMEN1NPC1RAB9AKMT2A
SCHEMBL8196446 0.84 CYP17A1 (0.51) GAAMEN1NPC1RAB9AKMT2A
SCHEMBL14518047 0.84 GAA (0.50) GAAMEN1NPC1RAB9AKMT2A
SCHEMBL29378002 0.82 ALDH1A1 (0.51) GAAMEN1NPC1RAB9AKMT2A
SCHEMBL536638 0.82 ALDH1A1 (0.51) GAAMEN1NPC1RAB9AKMT2A
SCHEMBL22026644 0.82 ALOX5 (0.50) GAAMEN1NPC1RAB9AKMT2A
SCHEMBL24865580 0.82 GAA (0.53) GAAMEN1NPC1RAB9AKMT2A
SCHEMBL15600499 0.82 GAA (0.47) GAAMEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111699250-A Carboxyesterase polypeptides for amide coupling 科德克希思公司 2020-09-22 CN claimed
EP-2691452-B1 CURABLE FLUOROELASTOMER COMPOSITION DU PONT (US) 2018-11-28 EP claimed
US-8816013-B2 Curable fluoroelastomer composition E I DU PONT DE NEMOURS AND COMPANY (US) 2014-08-26 US claimed
EP-2691452-A1 CURABLE FLUOROELASTOMER COMPOSITION E.I. Du Pont De Nemours And Company (US) 2014-02-05 EP claimed
US-20130072643-A1 CURABLE FLUOROELASTOMER COMPOSITION E. I. DU PONT DE NEMOURS AND COMPANY (US) 2013-03-21 US claimed
WO-2012135782-A1 CURABLE FLUOROELASTOMER COMPOSITION E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-10-04 WO claimed
CN-120081775-A Preparation method of N-aminoindole 山东海化集团有限公司 2025-06-03 CN disclosed
CN-111699250-B Carboxylesterase polypeptides for amide coupling 科德克希思公司 2024-01-09 CN disclosed
CN-115991884-A Resin microsphere with covalent bonding heavy metal ion probe and application thereof 华中师范大学 2023-04-21 CN disclosed
CN-114195676-B Biarylhydrazine compound and adduct thereof and application of compound in preparation of antitumor drugs 广州药本君安医药科技股份有限公司 2022-08-05 CN disclosed
CN-114195676-A Biarylhydrazine compound and adduct thereof and application of compound in preparation of antitumor drugs 广州药本君安医药科技股份有限公司 2022-03-18 CN disclosed
CN-114174288-A Methods of treatment with aminolevulinic acid synthase 2(ALAS2) modulators 安吉奥斯医药品有限公司 2022-03-11 CN disclosed
US-10821100-B2 Triazolone compounds as mPGES-1 inhibitors Ichnos Sciences SA (CH) 2020-11-03 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
US-5962496-A CENTRAL NERVOUS SYSTEM DISORDERS GLAXO WELLCOME SPA (IT) 1999-10-05 US disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed
US-5760059-A ANTAGONISTS OF EXCITATORY AMINO ACIDS, TREATMENT OF NEURODEGENERATIVE DISEASES GLAXO WELLCOME SPA (IT) 1998-06-02 US disclosed
CN-1133042-A Indole derivatives as NMDA antagonists GLAXO SPA (IT) 1996-10-09 CN disclosed
EP-0723541-A1 INDOLE DERIVATIVES AS NMDA ANTAGONISTS GLAXO WELLCOME S.p.A. (IT) 1996-07-31 EP disclosed
WO-1995010517-A1 INDOLE DERIVATIVES AS NMDA ANTAGONISTS GLAXO WELLCOME S.P.A. (IT) 1995-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10821100-B2 Triazolone compounds as mPGES-1 inhibitors PTGES, PTGS1, PTGIS GAA 1319/4885MEN1 4011/4885NPC1 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.